Nebivolol Approval Could Come In Mid-2007, Forest Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.
You may also be interested in...
Forest Will Delay Nebivolol NDA For CHF Pending FDA Review Of Hypertension Data
Company is currently wrapping up pharmacokinetic studies needed to respond to an “approvable” letter for hypertension NDA.
Forest Will Delay Nebivolol NDA For CHF Pending FDA Review Of Hypertension Data
Company is currently wrapping up pharmacokinetic studies needed to respond to an “approvable” letter for hypertension NDA.
Forest Labs Aims To Launch Once-Daily Namenda Ahead Of Generics
Alzheimer's line-extension is in Phase III, and first ANDA with paragraph IV certification for current twice-daily formula could be filed next fall.